United States Fabry Disease Treatment Market to Grow with a CAGR of 6.44% through 2029

International expansion and the tireless efforts of patient advocacy groups are expected to drive the United States Fabry Disease Treatment Market growth in the forecast period, 2025-2029.

According to TechSci Research report, “United States Fabry Disease Treatment Market – By Region, Competition, Forecast and Opportunities, 2029”, the United States Fabry Disease Treatment Market was valued at USD 492.11 million in 2023 and is anticipated to project impressive growth in the forecast period with a CAGR of 6.44% through 2029. This growth can be largely attributed to international expansion. As awareness and treatment options for Fabry disease increase, pharmaceutical companies are broadening their reach within the United States. They are actively seeking approvals and market access in various regions, thereby enhancing the availability of treatments for Fabry disease patients globally.

Additionally, patient advocacy groups and foundations focused on Fabry disease are gaining traction. These organizations play a vital role in raising awareness, supporting research, and advocating for improved access to treatment options. As advocacy efforts continue to grow, they will foster collaboration among patients, healthcare professionals, and pharmaceutical companies, ultimately influencing the development and accessibility of Fabry disease treatments.

The Fabry disease treatment market faced significant disruption due to the COVID-19 pandemic, particularly in its early stages. Patients receiving treatment in hospitals experienced delays and interruptions in drug infusion services. Moreover, COVID-19 infection led to changes in immune system functions among Fabry disease patients. A June 2022 article in PubMed indicated that the risk of severe COVID-19 in these patients was related to their immune system rather than Fabry disease itself. As a result, the complications of Fabry disease were worsened by COVID-19, and the lack of immediate medication had a notable negative impact on market growth. Nevertheless, the market is poised for substantial growth in the coming years, driven by advancements in Fabry disease treatment and a strong pipeline of products from key market players.

Several factors are contributing to this anticipated growth, including increased awareness of Fabry disease treatments, expanded research and development efforts, and a promising pipeline of products. Heightened awareness regarding Fabry disease treatment is crucial for both patients and healthcare professionals. Notably, awareness initiatives have been gaining momentum in countries such as the United States and the United Kingdom. For example, the National Fabry Disease Foundation (NFDF) has designated April as Fabry Disease Awareness Month in the United States. These campaigns aim to educate the public, patients, caregivers, and healthcare providers, leading to improved recognition, diagnosis, and management of Fabry disease, which in turn supports market growth during the study period.

Furthermore, the increase in research and development activities and funding dedicated to Fabry disease treatment is expected to further drive market expansion. For instance, in December 2022, Bio Sidus SA sponsored a clinical trial to evaluate the safety and efficacy of AGA BETA BS in patients with Fabry disease who had previously been treated and stabilized with Fabrazyme. Additionally, the market stands to benefit from various pipeline products related to Fabry disease that are poised to receive regulatory approvals, including those in Europe.

Browse over XX market data Figures spread through XX Pages and an in-depth TOC on "United States Fabry Disease Treatment Market.”

Based on distribution channel, Hospital pharmacies are poised to dominate the United States Fabry Disease Treatment Market. Fabry disease often requires complex treatment regimens, including enzyme replacement therapy (ERT), which necessitates specialized storage, handling, and administration facilities available primarily in hospital settings. Hospitals offer a wide range of services, including diagnostics and treatment of various medical conditions, making them central hubs for diagnosing and managing Fabry disease cases. Hospitals are equipped with experienced healthcare professionals who can efficiently administer ERT and provide comprehensive care to patients with Fabry disease, ensuring optimal treatment outcomes. Hospitals have established relationships with pharmaceutical companies, enabling them to secure a stable supply of Fabry disease treatment drugs and stay at the forefront of advancements in this field. These factors collectively position hospital pharmacies as the dominant players in the United States Fabry Disease Treatment Market, ensuring that patients receive the highest standard of care for this rare genetic disorder.

Based on region, The North-East region of the United States is strategically positioned to lead the Fabry Disease Treatment Market for several compelling reasons. It hosts some of the country’s most renowned medical institutions and research facilities, which are at the forefront of research and treatment development for Fabry disease. These institutions attract top talent and drive significant healthcare innovations. The North-East's higher population density creates a larger potential patient base and an increased demand for Fabry disease treatments. Furthermore, the region's strong healthcare infrastructure and high levels of insurance coverage ensure that patients have access to state-of-the-art therapies. The North-East's strategic location facilitates collaboration with pharmaceutical companies and clinical trial centers, further solidifying its dominance in the Fabry Disease Treatment Market. Considering these factors, it is evident that the North-East is poised to lead the advancement and commercialization of treatments for Fabry disease in the United States.

Major companies operating in United States Fabry Disease Treatment Market are:

• Sanofi SA
• Takeda Pharmaceutical Co Ltd
• Amicus Therapeutics Inc
• ISU Abxis Co Ltd
• JCR Pharmaceuticals Co Ltd
• Protalix BioTherapeutics Inc
• Chiesi Farmaceutici SpA
• Freeline Therapeutics Holdings PLC
• Yuhan Corp
• M6P Therapeutics

Download Free Sample Report

Customers can also request for 10% free customization on this report.

“The United States Fabry Disease Treatment Market is entering an exciting phase of innovation and transformation. As precision medicine, gene therapy, small molecule chaperone therapies, innovative drug delivery systems, telemedicine, and patient advocacy gain momentum, the outlook for Fabry disease patients is more promising than ever before. These trends hold the potential to not only improve treatment options but also enhance the overall quality of life for individuals living with Fabry disease. As research and development efforts continue to advance, the future for Fabry disease patients looks brighter than ever”, said Mr. Karan Chechi, Research Director of TechSci Research, a research-based management consulting firm.

“United States Fabry Disease Treatment Market, By Treatment Type (Chaperone Treatment, Enzyme Replacement Therapy, Organ-Specific Treatment, Substrate Reduction Therapy), By Drugs (Agalsidase Beta, Migalastat, Pipeline Drugs), By Route of Administration (Intravenous, Oral), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Region, Competition, Forecast & Opportunities, 2019-2029F”, has evaluated the future growth potential of United States Fabry Disease Treatment Market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in United States Fabry Disease Treatment Market.

Contact

TechSci Research LLC

420 Lexington Avenue, Suite 300,

New York, United States- 10170

Tel: +1-332-258-6602

Email: [email protected]

Website: www.techsciresearch.com